Last reviewed · How we verify
iv Procainamide
Procainamide is a Class IA antiarrhythmic that blocks cardiac sodium channels and slows conduction velocity to suppress abnormal electrical activity in the heart.
Procainamide is a Class IA antiarrhythmic that blocks cardiac sodium channels and slows conduction velocity to suppress abnormal electrical activity in the heart. Used for Atrial fibrillation and atrial flutter, Ventricular tachycardia, Premature ventricular contractions.
At a glance
| Generic name | iv Procainamide |
|---|---|
| Sponsor | Hospital General Universitario Gregorio Marañon |
| Drug class | Class IA antiarrhythmic agent |
| Target | Cardiac voltage-gated sodium channel |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Procainamide inhibits fast inward sodium current in cardiac tissue, which decreases the rate of depolarization and slows conduction through the atria and ventricles. It also has anticholinergic properties and prolongs the action potential duration and refractory period, making it effective for suppressing both atrial and ventricular arrhythmias.
Approved indications
- Atrial fibrillation and atrial flutter
- Ventricular tachycardia
- Premature ventricular contractions
- Wolff-Parkinson-White syndrome with rapid conduction
Common side effects
- Hypotension
- Lupus-like syndrome
- Agranulocytosis
- Nausea and vomiting
- Dizziness
- Proarrhythmic effects
Key clinical trials
- RAFF4 Trial: Vernakalant vs. Procainamide for Acute Atrial Fibrillation in the Emergency Department (PHASE4)
- Prevention of Post-Operative Cardiac Arrhythmias (PHASE4)
- Iv Amiodarone Versus Iv Procainamide to Treat Haemodynamically Well Tolerated Ventricular Tachycardia (PHASE4)
- Ajmaline Utilization in the Diagnosis and Treatment of Cardiac Arrhythmias (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- iv Procainamide CI brief — competitive landscape report
- iv Procainamide updates RSS · CI watch RSS
- Hospital General Universitario Gregorio Marañon portfolio CI